PDPK2P: A Potential Drug Target and Biomarker for Phosphatidyltransferase Family PLC/PKC

Target Name: PDPK2P

NCBI ID: G653650

PDPK2P

Other Name(s): 3-phosphoinositide dependent protein kinase-1 pseudogene | 3-phosphoinositide dependent protein kinase 2, pseudogene | LOC653650

PDPK2P: A Potential Drug Target and Biomarker for Phosphatidyltransferase Family PLC/PKC

Introduction

Phospholipidosis is a pathological condition characterized by the accumulation of phospholipids, including phosphatidylcholesterol (PC), in various cell types, leading to various physiological and pathological effects. The phosphatidyltransferase family PLC/PKC is involved in the regulation of lipid metabolism and has has been implicated in the development and progression of various diseases, including cardiovascular diseases, neurodegenerative diseases, and cancer. The PLC/PKC signaling pathway is also a potential drug target in diseases associated with inflammation and cellular signaling disruptions.

PDPK2P, a pseudogene associated with the PLC/PKC signaling pathway, has been identified as a potential drug target and biomarker. PDPK2P is a 3-phosphoinositide dependent protein kinase that is expressed in various cell types, including neurons, liver cells, and heart muscle cells. It plays a crucial role in the regulation of lipid metabolism, intracellular signaling, and cellular signaling pathways.

Domains and functions

PDPK2P consists of 114 amino acids, including a catalytic domain, two transmembrane domains, and an N-terminus. The catalytic activity of PDPK2P depends on its phosphorylation state, so it is a phosphatase that can regulate the phosphorylation of substrates through phosphorylation modification. The functions of PDPK2P are mainly reflected in the following aspects:

1. Regulate lipid metabolism

PDPK2P is part of the PLC/PKC pathway of the phosphatidyltransferase family and can phosphorylate PC, thereby increasing intracellular PC content. PC is one of the main components of the cell membrane and can affect the fluidity of the cell membrane, cell signaling, and intracellular transport. Increasing the content of PC can lead to a decrease in the fluidity of the cell membrane, a slowdown in signal transmission, and a decrease in intracellular transport capacity, thereby affecting cell function and metabolism.

2. Participate in cell signaling

PDPK2P is a key participant in multiple intracellular signal transduction pathways, such as PI3K/Akt signaling pathway, NF-kappa-B signaling pathway and TGF-β signaling pathway. These signal transduction pathways have an important impact on processes such as cell proliferation, differentiation, and apoptosis. Phosphorylation of PDPK2P can regulate the activity of these signal transduction pathways, thereby affecting cell function and metabolism.

3. Participate in intracellular transport

PDPK2P is an important component of various intracellular transport systems. It can phosphorylate PC and increase the content of PC in cells, thus increasing the fluidity of the membrane, allowing molecules to cross the cell membrane more easily. PDPK2P can also phosphorylate other membrane proteins, such as PMCA and PSMA, thereby affecting the speed and efficiency of intracellular transport.

4. Participate in tumor occurrence and development

PDPK2P is a key player in the occurrence and development of various tumors. It can phosphorylate PC and increase intracellular PC content, thereby providing energy for the growth and proliferation of tumor cells. PDPK2P can also phosphorylate other membrane proteins, such as PDGF receptors, thereby promoting the invasion and metastasis of tumor cells.

pharmacological significance

As a potential drug target, PDPK2P can be used to treat a variety of diseases. The phosphorylation status of PDPK2P can affect cell function and metabolism by regulating lipid metabolism, participating in cell signaling and intracellular transport. Therefore, PDPK2P can be used as a potential drug target for the treatment of various diseases.

Activation of PDPK2P can increase intracellular PC content, thereby inhibiting the growth and proliferation of tumor cells. It can also inhibit the invasion and metastasis of tumor cells, thereby providing new treatment directions for tumor patients. PDPK2P as a drug target in future cancer

Protein Name: 3-phosphoinositide Dependent Protein Kinase 2, Pseudogene

Functions: Phosphorylates and activates not only PKB/AKT, but also PKA, PKC-zeta, RPS6KA1 and RPS6KB1. May play a general role in signaling processes and in development (By similarity)

The "PDPK2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PDPK2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets